Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from GH Research ( (GHRS) ).
On November 6, 2025, GH Research PLC announced its financial results for the third quarter of 2025, highlighting significant operational losses. The company reported a loss from operations of $16.565 million for the quarter, compared to $12.621 million in the same period in 2024. Despite these losses, the company continues to focus on its research and development activities, as indicated by the substantial expenditure in this area. The financial results and business updates were made available through a press release and an investor presentation on the company’s website, reflecting GH Research’s ongoing commitment to transparency with its stakeholders.
The most recent analyst rating on (GHRS) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a company involved in the pharmaceutical industry, focusing on the development of novel treatments. The company is based in Dublin, Ireland, and is known for its research and development efforts in innovative therapies.
Average Trading Volume: 282,375
Technical Sentiment Signal: Strong Buy
Current Market Cap: $837.4M
For a thorough assessment of GHRS stock, go to TipRanks’ Stock Analysis page.